Claritev screens as deeply undervalued on headline multiples with modest insider buying, but a fresh negative news modifier, a confirmed technical downtrend, 3 consecutive earnings misses, and negative asymmetry keep the engine's stance at hold rather than buy.
Thesis pillars
- Deep Value Cheap Multiple→Stable
- Negative News Modifier Downgrade↓Deteriorating
- Cash Flow Quality Signal→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Feb 26, 2026
Claritev Corporation (CTEV) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $23.00, but acceptable to hold if already in. Reason: Market cap $390M below $400M minimum.
Claritev is a healthcare technology, data, and insights company that helps payers manage medical claims costs through out-of-network cost management, network, payment and revenue integrity, and data and analytics solutions, serving more than 750 clients and an estimated 60... Read more
Hold if already holding. Not a fresh buy at $23.00, but acceptable to hold if already in. Reason: Market cap $390M below $400M minimum. Chart setup: RSI 42 mid-range, Bollinger mid-band. Market cap $390M below $400M minimum. Not in investable universe. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Claritev Corporation
About Claritev Corporation
Claritev, a healthcare technology and data-analytics company with more than 45 years of claims experience, used its platform in 2025 to identify $25.0 billion in potential savings on $179.8 billion in claim charges across more than 750 payer clients. The company's two largest clients accounted for approximately 29.2% and 10.4% of 2025 revenue, respectively, together representing nearly 40% of the total.
Claritev sells primarily to payers — health plans, administrative-services-only platforms, and third-party administrators — who distribute its out-of-network cost management, network, payment and revenue integrity, and data and analytics solutions to more than 100,000 employers and plan sponsors covering an estimated 60 million consumers. Its PHCS Network provides contracted discounts across more than 1.4 million healthcare providers, and its platform accesses and processes claims before payment, a pre-payment position built on more than $500 million of cumulative capitalized software development and roughly 15 petabytes of managed data capacity. Revenue is typically recurring under multi-year contracts with larger clients and one-year auto-renewing contracts with smaller ones, though most agreements allow termination on short notice and contain no minimum utilization commitments. The 2025 Vision 2030 transformation plan, branded internally as THE TURN, aims to diversify Claritev's revenue beyond out-of-network claims and the commercial payer market while migrating cloud infrastructure to Oracle Cloud Infrastructure.
Show full overview
Claritev's own risk disclosure ties its business directly to retaining its largest accounts: the top two clients alone represented roughly 39.6% of 2025 revenue, and the company states it has previously experienced significant reductions in product usage and pricing pressure from major clients, with no minimum-utilization protections in most contracts. Ongoing consolidation among insurers compounds this exposure, since an acquired client could renegotiate terms or reduce claims volume even without formally terminating its contract, a dynamic Vision 2030's push into new lines of business and geographies is explicitly designed to offset.
See also: Healthcare · Health Information Services
From Claritev Corporation's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Claritev Corporation
Latest news
- NEWS Claritev Selected By General Dynamics Information Technology To Support The World Trade Center Health Program; Terms Not — benzinga Sep 22, 2026
- NEWS Barclays Maintains Overweight on Claritev, Raises Price Target to $40 — benzinga Aug 21, 2026 positive
- NEWS Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans — benzinga Aug 17, 2026 positive
- NEWS Wells Fargo Maintains Equal-Weight on Claritev, Raises Price Target to $30 — benzinga Aug 12, 2026 positive
- NEWS Claritev Analysts Raise Their Forecasts Following Q2 Earnings — benzinga Aug 10, 2026 positive
Generated 2026-10-29T11:08:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerlargest client29%10-K Item 1A: 'Our two largest clients accounted for approximately 29.2% and 10.4%, respectively, of our revenues for the year ended December 31, 2025.'
- LOWCustomersecond largest client10%10-K Item 1A: 'Our two largest clients accounted for approximately 29.2% and 10.4%, respectively, of our revenues for the year ended December 31, 2025.'
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02LOWStockholders approved an amendment to the 2020 Omnibus Incentive Plan on April 29, 2026, adding 2,375,000 shares for issuance; a routine equity-plan expansion, not an executive departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $23.00, but acceptable to hold if already in. Reason: Market cap $390M below $400M minimum. Chart setup: RSI 42 mid-range, Bollinger mid-band. Market cap $390M below $400M minimum. Not in investable universe. Analyst target $40.02 (+74.0%), stop $21.39 (−7.5%), A.R:R 6.2:1. Score 5.9/10, moderate confidence.
Analyst target: $40.02 (+74.0% upside). Analyst target $40.02 (+74.0%), stop $21.39 (−7.5%), A.R:R 6.2:1. Stop-loss: $21.39.
Market cap $390M below $400M minimum.
Claritev Corporation trades at a P/E of N/A (forward 3.1). TrendMatrix value score: 9.0/10. Verdict: Hold.
11 analysts cover CTEV with a consensus score of 4.1/5. Average price target: $46.
What does Claritev Corporation do?Claritev is a healthcare technology, data, and insights company that helps payers manage medical claims costs through...
Claritev is a healthcare technology, data, and insights company that helps payers manage medical claims costs through out-of-network cost management, network, payment and revenue integrity, and data and analytics solutions, serving more than 750 clients and an estimated 60 million consumers through their health plans. In 2025 the company identified $25.0 billion in potential savings on $179.8 billion in claim charges, while its two largest clients accounted for approximately 29.2% and 10.4% of revenue, respectively.